AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer

  • AstraZeneca Plc AZN and Daiichi Sankyo DSNKY announced detailed results from the positive DESTINY-Gastric02 Phase 2 trial of Enhertu (fam-trastuzumab deruxtecan-nxki).
  • The trial included HER2-positive metastatic and/or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma patients previously treated with a trastuzumab-containing regimen.
  • Detailed results provided a clinically meaningful and durable tumor response and were presented at the European Society for Medical Oncology (ESMO21) Congress 2021.
  • In the primary analysis of the DESTINY-Gastric02 trial, Enhertu (6.4 mg/kg) demonstrated a confirmed overall response rate (ORR) of 38% as assessed by independent central review (ICR). 
  • Three (3.8%) complete responses (CR) and 27 (34.2%) partial responses (PR) were observed in patients treated with Enhertu. 
  • After a median follow-up of 5.7 months, the median duration of response (DoR) of Enhertu was 8.1 months. 
  • The median progression-free survival (PFS) was 5.5 months. 
  • An exploratory endpoint of confirmed disease control rate (DCR) of 81% was seen.
  • The overall safety profile of Enhertu in DESTINY-Gastric02 was consistent with that seen in DESTINY-Gastric01. 
  • Price Action: AZN stock is down 1.86% at $55.55 during the market session on the last check Friday.
  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).
Posted In: BiotechNewsHealth CareGeneralBriefsESMO21gastric cancerPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!